Medical Xpress

APRIL 3, 2023

Yet, as many as two billion people are infected with Mycobaterium tuberculosis, the bacterium that causes tuberculosis, and are otherwise healthy and asymptomatic. Scientists who study TB look at those individuals who can tolerate and contain the infection in hopes of developing better treatments and vaccines.

Bacterium 81

Bacterium Containment Scientist Vaccination 81

Medical Xpress

MARCH 27, 2023

diff infection caused by multiple strains of the bacterium, including those that cause serious illness. Researchers are now using this compound to develop new drug candidates that might eventually offer a way to prevent serious C. A new study performed in mice has identified a compound that prevented C. diff infections in people.

Bacterium 83

Bacterium Scientist Development Drugs 83

Medical Xpress

MARCH 29, 2023

A large case-control study by international researchers at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan has found that people who carry certain genetic risk factors for gastric (stomach) cancer have a much greater risk if they have also been infected by the bacterium Helicobacter pylori.

Genetics 81

Genetics Bacterium Genome Genomics 81

Medical Xpress

MARCH 14, 2023

pylori) is an infectious bacterium that resides in the gastric mucosa and causes persistent gastric damage. If left untreated, it can also lead to the development of stomach cancer. Helicobacter pylori (H. pylori can cause chronic gastritis, peptic ulcers, and iron deficiency anemia. The World Health Organization classifies H.

Bacterium 69

Bacterium Development Research 69

pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition. The post Sanofi snaps up acne vaccine developer Origimm Bio appeared first on.

Vaccination 102

Vaccination Vaccine Development Hormones 102

Drug Discovery Today

MARCH 18, 2020

The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical company Microbiotix, Inc. to progress a novel treatment to tackle the bacterium that is responsible for gonorrhoea.

Bacterium 40

Bacterium Development 40

Drug Discovery World

AUGUST 7, 2023

Research published in Science shows that a naturally occurring bacterium discovered by GSK scientists – Delftia tsuruhatensis Tres Cantos 1 (TC1) – could be the basis for new anti-malarial interventions. The results suggest TC1 has potential to inhibit the development of all malaria parasites which affect humans (P. ovale and P.

Bacteria 52

Bacteria Bacterium Containment Scientist 52

Scienmag

OCTOBER 15, 2020

Credit: (Image: Chair of Molecular Infection Biology II / University of Wuerzburg / SCIGRAPHIX) More than half of the world’s population carries the bacterium Helicobacter pylori in their stomach mucosa.

RNA 93

RNA Bacterium Development Genetics 93

XTalks

SEPTEMBER 22, 2020

The strip did indeed work, showing a positive for the bacterium in about 16 hours and indicating spoilage a few hours after that. To test out this microneedle strip, the researchers injected a piece of raw fish with E. coli , salmonella and a non-contaminated control fluid. They also waited for it to, essentially, rot.

Contamination 98

Contamination Scientist Development Bacterium 98

Scienmag

MAY 18, 2021

Tuberculosis, a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), is typically the leading infectious cause of death globally, killing 1.2 million […].

Bacterium 72

Bacterium Research Development Medicine 72

Scienmag

OCTOBER 1, 2020

Work allows genomic monitoring for epidemic strains of Vibrio cholerae bacteria The evolution of epidemic and endemic strains of the cholera-causing bacterium Vibrio cholerae in Argentina has been mapped in detail by researchers at the Wellcome Sanger Institute, the London School of Hygiene and Tropical Medicine, the University of Cambridge and the (..)

Bacterium 75

Bacterium Bacteria Genome Genomics 75

Drug Discovery World

AUGUST 23, 2023

Earlier, they developed a device that enables researchers to grow ‘bacterial dark matter’, which are so-called unculturable bacteria. Ninety-nine percent of all bacteria are ‘unculturable’ and could not be grown in laboratories previously, and therefore not be mined for novel antibiotics. terrae ssp. Carolina.

Bacteria 52

Bacteria Bacterium Development Research 52

pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

pharmaphorum

SEPTEMBER 10, 2020

Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against coronavirus infections. The spray that will be developed alongside Destiny Pharma – called SPOR-COV – is a modified form of B. Image: Allonweiner at English Wikipedia.

Vaccination 132

Vaccination Vaccine Bacterium Antibody 132

pharmaphorum

SEPTEMBER 8, 2022

GBS is responsible for nearly half of all life-threatening infections in newborns, and around 15-25% of women carry the bacterium and risk transmitting it to their child in utero, during birth, or during their first months of life. It has previously also been given fast-track status.

Vaccination 52

Vaccination Vaccine Bacterium Licensing 52

Pharmaceutical Technology

SEPTEMBER 1, 2022

In the pursuit of improving patient care, the continued development of POC testing can help support future demand for rapid diagnosis and treatment, with opportunities to implement successful POC facilities expanding over the years as the technology has improved.

Manufacturing 130

Manufacturing Bacterium Reagent Production 130

pharmaphorum

DECEMBER 24, 2020

AMG 634 – a PDE4 inhibitor being investigated for TB and leprosy complication erythema nodosum leprosum (ENL) – is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights to the drug. million patients every year and causing over a million deaths.

Bacterium 52

Bacterium Licensing Licensing Development 52

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium.

Vaccination 98

Vaccination Vaccine Immune Response Bacterium 98

Scienmag

OCTOBER 7, 2020

Study will influence the global elimination strategy for yaws Genome sequencing has shed light on the re-emergence of the bacterium that causes yaws, a neglected tropical disease of the skin, bones and joints. The re-emergence followed a mass drug administration (MDA) campaign that aimed to eliminate the disease in Papua New Guinea.

Genome 40

Genome Genomics Bacterium Drugs 40

Drug Discovery World

NOVEMBER 22, 2022

The study was conducted on a patient that carried the bacterium Pseudomonas aeruginosa as part of their gut microbiome. Professor Craig MacLean, Professor at the Department of Biology, Oxford University, said: “Insights such as this are needed in order to develop new interventions to prevent resistant infections.

Bacteria 98

Bacteria Bacterium Development Drugs 98

XTalks

JUNE 14, 2022

Previous and emerging research on this bacterium has associated it with intrinsic multi-drug resistance and nosocomial infections (also referred to as hospital-acquired infections). The NasoSpray was developed to reduce non-apneic snoring. Green Pharmaceuticals Inc. is known for its brand of anti-snoring over-the-counter products.

Contamination 52

Contamination Bacterium Bacteria Branding 52

XTalks

JULY 25, 2023

“The approval of Cyfendus vaccine is symbolic of Emergent’s longstanding partnership with the US government and our shared commitment to helping protect public health,” said Dr. Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. What Is Anthrax? How Does Cyfendus Work?

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The bacterium then secretes pDNA-protein complexes, triggering an immune response to treat and prevent infection associated with the delivered genes.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

MARCH 21, 2022

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The work solves a nearly 20-year riddle about how the marine bacterium makes the warhead that is unique to the salinosporamide molecule and opens the door to future biotechnology to manufacture new anti-cancer agents.

Bacterium 52

Bacterium Scientist Clinical Trials Clinical Trials 52

Roots Analysis

NOVEMBER 11, 2023

The Centers for Disease Control and Prevention (CDC) recently issued a formal health advisory in response to an unprecedented outbreak of carbapenem-resistant Pseudomonas aeruginosa (CRPA), a bacterium notorious for its resistance to specific antibiotics, thereby instigating severe infections in affected individuals.

Contamination 52

Contamination Bacterium Branding Bacteria 52

pharmaphorum

MAY 31, 2022

billion in potential development milestones, to get its hands on the ASP3772 shot, which recently claimed a breakthrough designation from the FDA for the treatment of pneumococcal disease in older adults. GlaxoSmithKline has agreed a $3.3 GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax, with another $1.2

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

pharmaphorum

JANUARY 20, 2021

Then, in 2018, Ella developed an infection that would not respond to treatment and was told her lung transplant was her only option. This interrupts replication patterns and, ultimately, kills the bacterium.”. This interrupts replication patterns and, ultimately, kills the bacterium. I was really sick.

Bacteria 105

Bacteria Bacterium DNA Doctors 105

pharmaphorum

MARCH 2, 2022

diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections. diff since Sanofi ended development of its candidate in 2017, ahead of Valneva whose VLA84 has been shelved after phase 2 while it looks for a development partner.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

The Pharma Data

OCTOBER 19, 2020

. “From genetic evidence, we have good reason to believe that the strains of bacterium responsible for plague changed very little over this time period, so this is a fascinating result,” said study co-author Hendrik Poinar, a professor of anthropology at McMaster.

Bacterium 52

Bacterium Genetics Research Development 52

The Pharma Data

MAY 31, 2022

billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

JUNE 16, 2022

The Medicines and Healthcare products Regulatory Agency’s (MHRA) gave a conditional approval to Idefirix – an enzyme derived from the bacterium Streptococcus pyogenes that breaks down immunoglobulin G (IgG) antibodies in the body – in 2020. The post Hansa gets NICE okay for Idefirix in kidney transplant patients appeared first on.

Antibody 52

Antibody Bacterium Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 2, 2022

billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion upfront payment and up to $1.2

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

JULY 14, 2021

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range. The post Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar appeared first on.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

The Pharma Data

JUNE 14, 2023

Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime – a common occurrence in people with cystic fibrosis. This can lead to acute infection, and a person could develop sepsis that requires immediate treatment.

RNA 40

RNA Regulation Scientist Bacteria 40

Pfizer

JANUARY 27, 2023

Trachoma is a neglected tropical disease (NTD) caused by the bacterium Chlamydia trachomatis. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. An estimated 1.9 difficile may need to be discontinued.

Bacteria 75

Bacteria Medicine Containment Manufacturing 75

Drug Discovery World

OCTOBER 4, 2022

Rebecca McClellan, Scientific Program Manager, Research, Development & Communications, explains how scientists are learning more about the connections between the microbiome and human health to potentially develop first-in-class microbiome therapies.

Research 52

Research Bacteria Scientist Bacterium 52